

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	ī	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/043,951		01/11/2002	Leonid Beigelman	MBHB00,716-D (RPI No. 600	7085
20306	7590	04/07/2003			
		EHNEN HULB	EXAMINER		
300 SOUTI SUITE 320		ERDRIVE	LEWIS, PATRICK T		
CHICAGO, IL 60606				ART UNIT	DARCE VIIIANCE
				ARTUNIT	PAPER NUMBER
			•	1623	9
			DATE MAILED: 04/07/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.

	<u> </u>						
\•		Application No.	Applicant(s)				
	Offic Action Summan	10/043,951	BEIGELMAN ET AL.				
	Offic Action Summary	Examiner	Art Unit				
	The MAIL INCO DATE of the	Patrick T. Lewis	1623				
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status							
1)	Responsive to communication(s) filed on						
2a)□		– · s action is non-final.					
3)	,		osecution as to the morite is				
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
· <u> </u>	on of Claims						
	Claim(s) <u>1-45</u> is/are pending in the application.						
	4a) Of the above claim(s) is/are withdraw	n from consideration.					
	5) Claim(s) is/are allowed.						
	Claim(s) is/are rejected.						
	Claim(s) is/are objected to.		,				
	Claim(s) <u>1-45</u> are subject to restriction and/or el on Papers	ection requirement.					
9) The specification is objected to by the Examiner.							
			niner				
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
	If approved, corrected drawings are required in reply		•				
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) ☐ All b) ☐ Some * c) ☐ None of:							
	1. Certified copies of the priority documents have been received.						
;	2. Certified copies of the priority documents have been received in Application No						
	Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
 a) ☐ The translation of the foreign language provisional application has been received. 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. 							
Attachment(s)							
2) 🔲 Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal Pa	PTO-413) Paper No(s) stent Application (PTO-152)				

Application/Control Number: 10/043,951

Art Unit: 1623

DETAILED ACTION

Election/Restrictions

1. This application contains claims directed to the following patentably distinct species of the claimed invention wherein the nucleoside is: 1) cytidine, 2) uridine, 3) adenosine, 4) guanosine, 5) inosine, 6) L-cytidine, 7) L-uridine, 8) L-adenosine, 9) L-guanosine, 10) L-inosine, 11) arabino-cytidine, 12) arabino-uridine, 13) arabino-adenosine, 14) arabino-guanosine, 15) arabino-inosine, 16) L-arabino-cytidine, 17) L-arabino-uridine, 18) L-arabino-adenosine, 19) L-arabino-guanosine, 20) L-arabino-inosine, 21) ribo-thymidine, 22) arabino-thymidine, 23) L-ribo-thymidine, or 24) L-arabino-thymidine.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species (1-24) for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1-26 are generic. It would indeed impose an undue burden upon the examiner in charge of this application if the instant species requirement were not advanced as set forth herein.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

^

Application/Control Number: 10/043,951

Art Unit: 1623

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Page 3

Contacts

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patrick T. Lewis whose telephone number is 703-305-4043. The examiner can normally be reached on M-F 10:00 am to 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 703-308-4624. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-305-3014 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-

Patrick T. Lewis, PhD Examiner Art Unit 1623

ptl April 1, 2003

0196.

James O. Wilson

Supervisory Patent Examiner
Jechnology Center 1600